First-in-Human Study of the Pharmacokinetics and Antiviral Activity of IDX375, a Novel Nonnucleoside Hepatitis C Virus Polymerase Inhibitor
Antimicrobial Agents and Chemotherapy, 07/27/2012
de Bruijne J et al. – IDX375 was well absorbed and well tolerated by all of the study participants. A single–day 200–mg BID dose resulted in exposure–related anti–HCV activity with maximal 0.5 to 1.1 log10 reductions in plasma HCV RNA. These observations support further clinical investigations of IDX375.